Home / Oncology (page 137)

Oncology

OncoMed to Investigate the Combination of its Experimental Cancer Drug with Lilly’s Alimta in Lung Cancer

OncoMed Pharmaceuticals, Inc. has teamed up with Eli Lilly and Company to test a combination of the companies’ drugs for treatment of lung cancer. The companies announced that they have entered into an agreement, under which OncoMed’s anti-DLL4 antibody, demcizumab, is being tested in combination with Lilly’s lung cancer drug, …

Read More »

Myriad and AstraZeneca Expand Companion Diagnostic Collaboration into Lynparza Study in Pancreatic Cancer Patients

Myriad Genetics, Inc. and AstraZeneca have expanded their companion diagnostic collaboration to include the utilization of Myriad’s diagnostic test to identify best responders to AstraZeneca’s investigational pancreatic cancer drug. The companies said that under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used prospectively to identify …

Read More »

Researchers Develop New Drug Candidate that Shows Potential in Treating Rare Leukemia

University of Michigan Comprehensive Cancer Center researchers have developed a new potential drug candidate that shows promise against a rare type of blood cancer, as well as potential in prostate cancer. The new drug candidate showed potential in laboratory studies against a rare type of acute leukemia. Additionally, separate studies …

Read More »

Catamaran Report Finds Drug Inflation and Increased Specialty Utilization Drives Increase in Drug Trend

Increased specialty utilization and drug inflation were the driving factors for overall drug trend more than doubling in 2014, according to a new report. Pharmacy Benefit Manager (PBM) Catamaran Corp. today released its annual Informed Trends report for 2014. Overall commercial drug trend was 5.7 percent in 2014, more than …

Read More »

Merck Teams Up with Syndax to Test Cancer Combination Regimen

Merck has teamed up with privately-held Syndax Pharmaceuticals to test combining Syndax’s investigational epigenetic therapy, entinostat, with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in cancer patients. The companies announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of this novel combination regimen in patients …

Read More »

Merck Serono and Intrexon Strike CAR-T Therapy Collaboration

Merck Serono is partnering with Intrexon Corporation to develop Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. The companies announced today that they have entered an exclusive strategic collaboration and license agreement for CAR-T cancer drugs, advancing Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s …

Read More »

Novartis Enters $750 Million Immuno-Oncology Collaboration with Aduro Biotech

Swiss drugmaker Novartis is increasing its efforts in immuno-oncology, entering a $750 million research, development and commercialization agreement with Aduro Biotech, Inc. The companies announced a collaboration for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the Stimulator of …

Read More »

RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …

Read More »